E-mail this story
Will Supreme Court's take on gene patents help Myriad?
While the Supreme Court’s decision to forbid patents on human genes knocked out Myriad Genetics' long-guarded patent on two genes linked to breast cancer, the Utah-based company’s stock still rose soon after the news broke. That bit of investor optimism may have been due to the court’s decision to allow patenting of cDNA, which they called "synthetically created" – though it’s unclear if that optimism is warranted, doctors pointed out.
By Amina Khan
June 14, 2013